Author/Authors :
Darbandi، B نويسنده Pediatric Hematologist and Oncologist,: Pediatrics Growth Disorders Research Center, 17th Sharivar Hospital, Guilan University of Medical Sciences, Rasht, Iran , , Noghbaei، M نويسنده Pediatrician, 31thKhordad Hospital, Manjil, Iran , , Mehrabian، F نويسنده Health Service Management,Guilan University of Medical Sciences. Rasht,Iran , , Jafroodi، M نويسنده Pediatric Hematologist and Oncologist,: Pediatrics Growth Disorders Research Center, 17th Sharivar Hospital, Guilan University of Medical Sciences, Rasht, Iran ,
Abstract :
Background
Glucose-6-phosphate dehydrogenase (G6PD)
enzyme deficiency is one of the prevalent disorders in
Guilan province, northern Iran, causing many patients
to suffer from acute hemolysis. This disease has
imposed tremendous costs both on patients and
Health systems.
The aim of this study was to compare the direct costs
of favism treatment on patients and health system
with G6PD enzyme screening test.
Materials and Methods
In this descriptive prospective study, the medical and
hospital costs of acute hemolysis due to G6PD
deficiency were calculated and compared with the
expenses of screening newly born infants for this
disorder in Rasht. Data was collected by a
questionnaire.Student’s t-Test and chi-squared test
were recruited and data was analyzed using SPSS
ver. 20.
Results
In this study, 101 hospitalized patients with favism
(72 male and 29 female) admitted from October 2011
to the end of September 2012 were included. The
average cost of treatment for these patients was
approximately 726000000Rials (for each patient
7190000 Rials), which was about half of the cost of
screening for all newborn infants in Rasht during this
period.
Conclusion
The cost of G6PD enzyme screening in Rasht is
substantially lower than the cost of treating
hospitalized patients with Favism
